Eagle Pharmaceuticals (EGRX) Posts Mixed Q1 Results

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of ($0.36), $0.10 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $5 million versus the consensus estimate of $3.2 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Circle Internet stock climbs on TD Cowen upgrade, Fed rate hike
• B.Riley Assumes Anika Therapeutics (ANIK) at Buy